A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer.

ABSTRACT:

Background

Antiangiogenic agents provides an optional treatment strategy for patients with metastatic breast cancer. The present study was conducted to evaluate the efficacy and safety of anlotinib as third-line or above therapy for patients with HER-2 negative metastatic breast cancer.

Methods

Patients with HER-2 negative metastatic breast cancer who have failed from prior therapy and treated with anlotinib monotherapy or combined with chemotherapy or immunotherapy from June 2018 to December 2020 were retrospectively analyzed based on real-world clinical practice. The primary end point was progression free survival (PFS). Secondary end points included objective response rate (ORR), disease control rate (DCR), overall survival (OS) and safety.

Results

47 patients with

SUBMITTER: Shao Y 

PROVIDER: S-EPMC9366600 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature